Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose.

Abstract

AIMS:

In atrial fibrillation (AF) patients 150 mg b.i.d. dabigatran is the standard dose, yet guidelines recommend 110 mg b.i.d. when bleeding risk is high. It is unknown to which extend these recommendations are followed in patients switching from vitamin K antagonist (VKA) to dabigatran. The aim of this study was to investigate if AF patients are switched from VKA to the appropriate dose of dabigatran.

METHODS AND RESULTS:

Using nationwide registries (22 August 2011 to 31 December 2012), we identified VKA-experienced AF patients with available creatinine values who switched to dabigatran. European guidelines criteria 2012 on dabigatran dosing were examined: age ≥80 years, HAS-BLED ≥3, estimated glomerular filtration rate (eGFR)<50 mL/min/1.73 m2, or use of interacting drugs. We identified 1626 VKA-experienced AF patients who switched to dabigatran 110 mg (820 patients) or 150 mg (806 patients). Patients who switched to 110 mg compared with 150 mg were older [median age 82 years (Q1-Q3: 77-86) vs. 68 years (Q1-Q3: 64-74)], more often females (54% vs. 35%), had a higher comorbidity burden, higher proportion with CHA2DS2-VASc score ≥2 (98% vs. 80%), and more with a HAS-BLED score ≥3 (46% vs. 28%). Patients switched to 110 mg had a higher absolute risk of mortality compared with patients switched to 150 mg. Overall, 26% were inappropriately dosed and 14% were switched to 110 mg although the higher dose was indicated. Furthermore, 39% of patients switched to 150 mg fulfilled one or more criteria for 110 mg, this mostly driven by high HAS-BLED scores (28.2% of patients on 150 mg). Female sex, age ≥80 years, eGFR < 50 mL/min/1.73 m2, drugs interacting with dabigatran, and prior bleeding were associated with switch to 110 mg. Patients inappropriately dosed had similar risk of mortality as patients appropriately dosed.

CONCLUSION:

Among VKA-experienced AF patients one in four were switched to a dabigatran dose contrary to guideline recommendations.

• Authors: Naja Emborg Vinding, Laila Staerk, Gunnar Hilmar Gislason, Christian Torp-Pedersen, Anders Nissen Bonde, Rasmus Rørth, Christina J-Y Lee, Jonas Bjerring Olesen, Lars Køber, Emil Loldrup Fosbøl
• Journal: European heart journal. Cardiovascular pharmacotherapy (Eur Heart J Cardiovasc Pharmacother) Vol. 7 Issue 1 Pg. 20-30 (01 16 2021) ISSN: 2055-6845 [Electronic] England
• PMID: 31730151 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: [email protected].

Chemical References

• Vitamin K
• Dabigatran

Topics

• Aged
• Aged, 80 and over
• Atrial Fibrillation (drug therapy)
• Dabigatran (administration & dosage, adverse effects)
• Dose-Response Relationship, Drug
• Female
• Humans
• Male
• Middle Aged
• Vitamin K (antagonists & inhibitors, therapeutic use)